All In Biotech

Drug Trial Radar · NCT06952010

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

303

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

May 31, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
First posted
Apr 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.

Conditions

  • Solid Tumor
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Immune Sensitive Tumor

Interventions

  • XB628Biological

    Intravenous infusion(s)

  • ZanzalintinibDrug

    Oral tablet(s)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Cohort: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: 21 days
  2. Dose Escalation Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 27 months
  3. Dose Expansion Cohort: Objective Response Rate (ORR)Time frame: Up to 27 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Exelixis Clinical Site #5

    San Francisco, California · Recruiting

  • Exelixis Clinical Site #4

    New Haven, Connecticut · Recruiting

  • Exelixis Clinical Site #8

    Tampa, Florida · Recruiting

  • Exelixis Clinical Site #10

    Boston, Massachusetts · Recruiting

  • Exelixis Clinical Site #11

    Boston, Massachusetts · Recruiting

  • Exelixis Clinical Site #6

    St Louis, Missouri · Recruiting

  • Exelixis Clinical Site #7

    New York, New York · Recruiting

  • Exelixis Clinical Site #1

    Hickory, North Carolina · Recruiting

  • Exelixis Clinical Site #3

    Nashville, Tennessee · Recruiting

  • Exelixis Clinical Site #9

    Houston, Texas · Recruiting

  • Exelixis Clinical Site #2

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.